Supplementary Material

Exclusions from the analysis cohort

The analysis cohort included 226 participants (RYGB n=161, VSG n=65), excluding 14 who underwent adjustable gastric banding and 2 who underwent VSG with preexisting conditions that could impact nutritional biomarkers (1 with osteogenesis imperfecta and 1 with anemia of chronic disease). Three participants subsequently developed chronic inflammatory systemic illness, which may influence nutritional biomarkers: multiple sclerosis (n=2, data excluded from month 48 onwards and month 60 only, respectively) and juvenile rheumatoid arthritis (n=1, data excluded from month 24 onwards).

Supplementary Statistical Analyses

Analyses to identify predictors of nutritional status: The GLMM approach was used to identify predictors of nutritional status 1 to 5 years post-operatively after weight stabilization. Prespecified variables included visit, surgery type, sex, race, caregiver educational level and baseline nutritional level as fixed effects, and study center as random effects. Visit-by-surgery interaction terms were not significant and therefore excluded from final models. Weight change between visits and self-reported multivitamin use were included as time-varying covariates. Additional variables were included as time-varying covariates for specific models: acid suppression medication for ferritin, transferrin and vitamin B12; hsCRP for ferritin and transferrin; vitamin D supplement usage for vitamin D and PTH; vitamin B12 supplement usage for vitamin B12; and calcium supplement usage for PTH.

Sensitivity analyses and analyses to account for missing data: Missing data were accounted for by use of the GLMM approach incorporating maximum likelihood estimation and assuming missing at random. The number of observations at each time-point for each nutritional

variable is included in the tables. Additionally, sensitivity analyses were carried out using multiple imputation. Results reported are from models that do not include multiple imputation. The sensitivity analyses, conducted using multiple imputation methods, did not alter the interpretation of the findings in this study (data not shown).¹⁵

Sensitivity analyses for models examining pregnancy and menstrual frequency: Models were fitted for both the continuous and categorical expression for each nutrient biomarker. Pregnancy status at each visit was considered positive in the model if the woman was either currently pregnant or within 6-months post-partum. Excluding the visits for women affected by pregnancy and/or low menstrual frequency also did not alter the interpretation of the findings except that weight gain was now associated with increasing B12 level (p=0.04).

Supplemental Table 1: Prevalence of abnormal values in nutritional measures over the five years after gastric bypass or sleeve gastrectomy surgery in adolescents.

Visit	Baseline	6 months	Year 1	Year 2	Year 3	Year 4	Year 5	<i>P</i> -value for comparison of values between visits [†]		
Abnormal nutritional biomarker	n (%) [95%CI]	n (%) [95%Cl]	n (%) [95%CI]	Baseline to 1y	1y to 5y linear trend	Baseline to 5y				
Ferritin: <10 ug/L	females and	<20 ug/L male:	S							
Gastric Bypass	4 (2.5) [0.7, 6.3] N=160	23 (16.9) [10.6, 23.2] N=136	40 (28.2) [21.0, 35.6] N=142	72 (54.6) [46.0, 63.0] N=132	83 (64.3) [56.1, 72.6] N=129	84 (70.0) [61.8, 78.2] N=120	87 (71.3) [63.3, 79.3] N=122	<0.0001	<0.0001	<0.0001
Sleeve Gastrectomy	7 (11.1) [3.3, 18.9] N=63	9 (17.3) [7.0, 27.6] N=52	13 (23.6) [12.4, 37.0] N=55	18 (36.7) [23.2, 50.2] N=49	14 (31.8) [18.1, 45.6] N=44	24 (49.0) [35.0, 63.0] N=49	19 (45.2) [30.2, 60.3] N=42	ns 0.20	0.01	0.002
Transferrin: > 382	2 mg/d female	es and > 392 m	g/dL males							
Gastric Bypass	1 (0.6) [0, 1.8] N=160	2 (1.5) [0, 3.5] N=136	5 (3.5) [0.5, 6.6] N=142	11 (8.3) [3.6, 13.0] N=132	17 (13.2) [7.3, 19.0] N=129	18 (15.0) [8.6, 21.4] N=120	19 (15.6) [9.1, 22.0] N=122	ns 0.69	<0.0001	0.02
Sleeve Gastrectomy	0 na N=63	0 na N=51	0 na N=55	0 na N=49	0 na N=44	3 (6.1) [0, 12.8] N=42	2 (4.8) [0, 11.2] N=42	Not estimable	ns 0.07	Not estimable
Vitamin B12: < 14										
Gastric Bypass	1 (0.6) [0, 1.9] N=159	3 (2.2) [0, 4.7] N=136	7 (4.9) [1.4, 8.5] N=142	14 (10.6) [5.4, 15.9] N=132	10 (7.8) [3.1, 12.4] N=129	20 (16.7) [10.0, 23.3] N=120	14 (11.5) [5.8, 17.1] N=122	ns 0.45	0.003	ns 0.06
Sleeve Gastrectomy	0 na N=63	2 (3.8) [0, 9.1] N=52	4 (7.3) [0.4, 14.1] N=55	1 (2.0) [0, 6.0] N=49	3 (6.8) [0, 14.3] N=44	3 (6.1) [0, 12.8] N=49	3 (7.1) [0, 14.9] N=42	Not estimable	ns 0.72	Not estimable
Vitamin B1: eryth	rocvte transk	cetolase activit	v coefficient ≥1	.30						
Gastric Bypass	2 (1.3) [0, 3.1] N=154	1 (0.8) [0, 2.2] N=133	3 (2.2) [0, 4.6] N=137	1 (0.8) [0, 2.3] N=126	1 (0.8) [0, 2.3] N=127	1 (0.9) [0, 2.5] N=116	1 (0.9) [0, 2.6] N=113	Not estimable	Not estimable	Not estimable
Sleeve Gastrectomy	0 na N=61	1 (2.0) [0, 5.8] N=51	0 na N=56	0 na N=48	0 na N=44	0 na N=43	0 na N=39	Not estimable	Not estimable	Not estimable
Folate: ≤ 5.8 ng/n	ıL									
Gastric Bypass	4 (2.5) [0.1, 5.0] N=158	22 (16.2) [10.0, 22.4] N=136	13 (9.2) [4.4, 13.9] N=142	7 (5.3) [1.5, 9.2] N=131	6 (4.7) [1.0, 8.3] N=129	2 (1.7) [0, 4.0] N=120	1 (0.8) [0, 2.4] N=122	ns 0.19	0.0007	ns 0.95
Sleeve Gastrectomy	1 (1.6) [0, 4.7]	8 (15.4) [5.6, 25.2]	10 (18.5) [8.2, 28.9]	4 (8.2) [0.5, 15.8]	4 (9.1) [0.6, 17.6]	3 (6.2) [0, 13.1]	2 (4.8) [0, 11.2]	ns 0.09	0.04	ns 0.98

Vitamin A: <301 ug/L	99 8 99 8 8 8 8 8										
Gastric Bypass 9 (5.7) 28 (20.9) 19 (13.4) 24 (18.3) 21 (16.5) 21 (17.5) 19 (15.7) ns ns ns ns ns [2.1, 9.3] [14.0, 27.8] [7.8, 19.0] [11.7, 24.9] [10.1, 23.0] [10.7, 24.3] [9.2, 22.2] 0.10 0.67 0.09 N=158 N=158 N=134 N=142 N=131 N=127 N=120 N=121 Sleeve 3 (4.9) 2 (4.0) 2 (3.6) 1 (2.1) 2 (4.5) 2 (4.1) 3 (7.0) ns ns ns ns Gastrectomy [0, 10.3] [0, 9.4] [0, 8.6] [0, 6.1] [0, 10.7] [0, 9.6] [0, 14.6] 0.99 0.31 0.99 N=61 N=50 N=55 N=48 N=44 N=49 N=43	99 8 99 8 8 8 8 8										
[2.1, 9.3] [14.0, 27.8] [7.8, 19.0] [11.7, 24.9] [10.1, 23.0] [10.7, 24.3] [9.2, 22.2] 0.10 0.67 0.09 N=158 N=158 N=134 N=142 N=131 N=127 N=120 N=121 Sleeve 3 (4.9) 2 (4.0) 2 (3.6) 1 (2.1) 2 (4.5) 2 (4.1) 3 (7.0) ns ns ns Gastrectomy [0, 10.3] [0, 9.4] [0, 8.6] [0, 6.1] [0, 10.7] [0, 9.6] [0, 14.6] 0.99 0.31 0.99 N=61 N=50 N=55 N=48 N=44 N=49 N=43 25-OH Vitamin D: < 20.1 ng/mL	s 99 s 32										
Sleeve 3 (4.9) 2 (4.0) 2 (3.6) 1 (2.1) 2 (4.5) 2 (4.1) 3 (7.0) ns ns ns Gastrectomy $\begin{bmatrix} 0, 10.3 \end{bmatrix} \begin{bmatrix} 0, 9.4 \end{bmatrix} \begin{bmatrix} 0, 8.6 \end{bmatrix} \begin{bmatrix} 0, 6.1 \end{bmatrix} \begin{bmatrix} 0, 10.7 \end{bmatrix} \begin{bmatrix} 0, 9.6 \end{bmatrix} \begin{bmatrix} 0, 9.6 \end{bmatrix} \begin{bmatrix} 0, 14.6 \end{bmatrix} 0.99 0.31 0.99$ N=61 N=50 N=55 N=48 N=44 N=49 N=43	99 8 32 8										
Gastrectomy [0, 10.3] [0, 9.4] [0, 8.6] [0, 6.1] [0, 10.7] [0, 9.6] [0, 14.6] 0.99 0.31 0.99 N=61 N=50 N=55 N=48 N=44 N=49 N=43 25-OH Vitamin D: < 20.1 ng/mL	99 8 32 8										
N=61 N=50 N=55 N=48 N=44 N=49 N=43 25-OH Vitamin D: < 20.1 ng/mL	s 32 s										
25-OH Vitamin D: < 20.1 ng/mL	32 S										
	32 S										
0 (1 0 0 10 10 10 10 10 10 10 10 10 10 10 1	32 S										
Gastric Bypass 71 (44.6) 42 (31.3) 52 (36.6) 64 (48.9) 63 (48.8) 63 (52.5) 61 (51.3) ns 0.005 ns	3										
[36.9, 52.4] [23.3, 39.2] [28.7, 44.5] [40.3, 57.4] [40.2, 57.5] [43.6, 61.4] [42.3, 60.2] 0.54 0.82											
N=159 N=134 N=142 N=131 N=129 N=120 N=119											
Sleeve 12 (19.4) 12 (23.5) 13 (23.6) 17 (34.7) 15 (34.1) 14 (29.2) 14 (33.3) ns ns ns ns Gastrectomy [9.5, 29.2] [11.9, 35.2] [12.4, 34.9] [21.4, 48.0] [20.1, 48.1] [16.3, 42.0] [19.1, 47.6] 0.99 0.43 0.70	U										
Gastrectomy [9.5, 29.2] [11.9, 35.2] [12.4, 34.9] [21.4, 48.0] [20.1, 48.1] [16.3, 42.0] [19.1, 47.6] 0.99 0.43 0.70 N=62 N=51 N=55 N=49 N=44 N=48 N=42											
PTH: > 88 pg/mL											
Gastric Bypass 17 (10.7) 6 (4.4) 8 (5.6) 11 (8.4) 16 (12.4) 19 (16.1) 20 (16.4) ns 0.001 ns											
[5.9, 15.5] [1.0, 7.9] [1.8, 9.4] [3.6, 13.2] [6.7, 18.1] [9.5, 22.7] [9.8, 23.0] 0.65 0.73	3										
N=159 N=135 N=142 N=131 N=129 N=118 N=122 Sleeve 1 (1.6) 0 1 (1.8) 1 (2.0) 1 (2.3) 1 (2.1) 0 Not Not Not	\t										
Gastrectomy [0, 4.7] na [0, 5.3] [0, 6.0] [0, 6.7] [0, 6.3] na estimable estimable estimable											
N=62 N=50 N=55 N=48 N=44 N=47 N=41											
Albumin: < 3.5 g/dL											
Gastric Bypass 7 (4.4) 0 0 2 (1.5) 0 1 (0.8) 3 (2.5) Not Not Not Not [1.2, 7.5] na na [0, 3.6] na [0, 2.4] [0, 5.2] estimable estimable estimable											
[1.2, 7.5] na na [0, 3.6] na [0, 2.4] [0, 5.2] estimable estimable estimab N=160 N=138 N=142 N=133 N=128 N=122 N=122	able										
Sleeve 0 0 1 (1.8) 1 (2.0) 0 1 (2.0) Not Not Not	ot										
Gastrectomy na na [0, 5.3] [0, 6.0] na [0, 6.0] estimable estimable estimab											
N=63 N=52 N=55 N=49 N=44 N=49 N=44											
hs-CRP: >1 mg/dL											
Gastric Bypass 44 (27.5) 13 (9.5) 7 (4.9) 7 (5.3) 7 (5.4) 8 (6.6) 11 (9.1) <0.0001 ns 0.0008	08										
[20.6, 34.4] [4.6, 14.4] [2.0, 9.9] [1.5, 9.2] [1.5, 9.3] [2.2, 11.0] [4.0, 14.2] 0.18 N=160 N=137 N=142 N=131 N=129 N=121 N=121											
Sleeve 12 (19.0) 7 (13.5) 6 (10.9) 4 (8.2) 4 (9.1) 6 (12.2) 6 (14.0) ns ns ns	3										
Gastrectomy [9.4, 28.7] [4.2, 22.7] [2.7, 19.2] [2.2, 19.6] [2.5, 21.7] [3.1, 21.4] [3.6, 24.3] 0.72 0.36 0.99											
N=63 N=52 N=55 N=49 N=44 N=49 N=43											
Nutrient Deficiency 2 or more deficiencies											
Gastric Bypass 19 (11.9) 31 (22.5) 40 (28.2) 61 (45.2) 67 (51.2) 67 (53.6) 73 (58.9) 0.003 <0.0001 <0.000	J01										
[6.9, 16.9] [15.5, 29.4] [20.8, 35.6] [36.8, 53.6] [42.6, 59.7] [44.9, 62.3] [50.2, 67.5] N=160 N=138 N=142 N=135 N=131 N=125 N=124											
Sleeve 4 (6.4) 9 (17.3) 10 (17.9) 11 (22.4) 9 (20.0) 9 (18.4) 12 (27.3) ns ns ns	:										
Gastrectomy [0.3, 12.4] [7.0, 27.6] [7.8, 27.9] [10.8, 34.1] [8.3, 31.7] [7.5, 29.2] [14.1, 40.4] 0.34 0.45 0.09											

	N=63	N=52	N=56	N=49	N=45	N=49	N=44				
Nutrient Deficiency 3 or more deficiencies											
Gastric Bypass	5 (3.1)	14 (10.1)	8 (5.6)	22 (16.3)	22 (16.8)	28 (22.4)	24 (19.4)	ns	0.0001	0.0005	
	[1.0, 7.1]	[5.1, 15.2]	[1.8, 9.4]	[10.1, 22.5]	[10.4, 23.2]	[15.1, 29.7]	[12.4, 26.3]	0.88			
	N=160	N=138	N=142	N=135	N=131	N=125	N=124				
Sleeve	1 (1.6)	1 (1.9)	3 (5.4)	3 (6.1)	3 (6.7)	4 (8.2)	1 (2.3)	ns	ns	ns	
Gastrectomy	[0, 4.7]	[0, 10.3]	[1.1, 14.9]	[1.3, 16.9]	[1.4, 18.3]	[2.3, 19.6]	[0, 12.0]	0.94	0.72	1.00	
	N=63	N=52	N=56	N=49	N=45	N=49	N=44				

[†] P-values are from generalized linear mixed models performed using a logit link function. Tukey-Kramer adjustment used when testing differences between baseline and year 1 and baseline and year 5 time-points. A linear model was fitted to test for trend between year 1 and year 5.

Supplemental Table 2: Reported intake of nutrient supplements, nutritionally-relevant medications, pregnancy and menstrual frequency over the 5 years after bariatric surgery, [n/N (%)]

ıriable	Baseline	6 months	Year 1	Year 2	Year 3	Year 4	Year 5
pplement Intake							
ulti-vitamins							
	106/157 (68%)	130/142 (92%)	128/140 (91%)	102/135 (76%)	87/129 (64%)	81/126 (64%)	75/131 (57%)
Sleeve Gastrectomy	57/62 (92%)	47/52 (90%)	45/55 (82%) [′]	33/51 (65%) [°]	28/48 (58%)	33/50 (66%)	20/48 (42%)
llcium							
Gastric Bypass	53/153 (35%)	118/141 (84%)	111/140 (79%)	85/133 (654%)	68/127 (54%)	60/125 (48%)	46/129 (36%)
Sleeve Gastrectomy	29/62 (47%)	47/52 (90%)	37/55 (67%)	27/50 (54%)	20/48 (42%)	13/50 (26%)	12/48 (25%)
tamin D							
Gastric Bypass	24/124 (19%)	39/133 (29%)	44/134 (33%)	42/130 (32%)	36/123 (29%)	35/124 (28%)	35/127 (28%)
Sleeve Gastrectomy	19/55 (34%)	32/47 (68%)	24/53 (45%)	21/50 (42%)	25/47 (53%)	10/50 (20%)	13/48 (27%)
on							
Gastric Bypass	13/149 (9%)	37/142 (26%)	40/138 (29%)	39/131 (30%)	38/126 (30%)	41/127 (32%)	37/129 (29%)
Sleeve Gastrectomy	15/56 (27%)	13/48 (27%)	16/55 (29%)	12/50 (24%)	10/48 (21%)	11/50 (22%)	10/48 (21%)
2 oral							
Gastric Bypass	32/150 (21%)	63/143 (44%)	52/137 (38%)	51/133 (38%)	34/125 (27%)	40/125 (32%)	34/127 (27%)
Sleeve Gastrectomy	13/57 (23%)	32/48 (67%)	29/54 (54%)	24/50 (48%)	17/48 (35%)	13/50 (26%)	8/48 (17%)
2 shot							
Gastric Bypass	1/160 (0.6%)	23/144 (16%)	25/1 (18%)	27/136 (20%)	22/129 (17%)	26/129 (20%)	23/135 (17%)
Sleeve Gastrectomy	0/62 (0%)	2/52 (4%)	3/55 (5%)	5/51 (10%)	6/48 (12%)	9/53 (17%)	13/48 (27%)
ther B12 oral or shot							
Gastric Bypass	33/160 (21%)	82/144 (57%)	73/140 (52%)	70/136 (52%)	54/129 (42%)	56/129 (43%)	53/135 (39%)
Sleeve Gastrectomy	13/62 (21%)	32/52 (62%)	31/55 (56%)	28/51 (55%)	22/48 (46%)	20/53 (38%)	18/48 (38%)
itritionally Relevant Me	edication Intake	•					
etformin							
Gastric Bypass	43/161 (27%)	5/145 (3%)	5/144 (4%)	1/139 (1%)	0/132	1/132 (1%)	1/137 (1%)
Sleeve Gastrectomy	15/65 (23%)	2/53 (4%)	1/59 (2%)	1/51 (2%)	1/49 (2%)	2/53 (4%)	1/50 (2%)

Acid Suppression Gastric Bypass Sleeve Gastrectomy	24/161 (15%) 9/65 (14%)	53/145 (37%) 11/53 (21%)	30/144 (21%) 10/59 (17%)	19/139 (14%) 5/51 (10%)	14/132 (11%) 4/49 (8%)	8/132 (6%) 5/53 (9%)	11/137 (8%) 2/50 (4%)
Females only							
Pregnancy							
Gastric Bypass Sleeve Gastrectomy	0/126 (0%) 0/44 (0%)	0/126 (0%) 1/44 (2%)	2/126 (2%) 2/44 (5%)	7/126 (6%) 3/43 (7%)	6/126 (5%) 1/43 (2 %)	11/125 (9%) 3/43 (7%)	10/124 (8%) 3/43 (7%)
Periods/Year							
Gastric Bypass	N=116		N=108	N=111	N=101	N=105	N=105
0-3	18 (16%)		20 (18%)	20 (18%)	13 (13%)	18 (17%)	22 (21%)
4-9	30 (26%)		17 (16%)	21 (19%)	26 (26%)	24 (23%)	26 (25%)
10+	68 (59%)		71 (66%)	70 (63%)	62 (61%)	63 (60%)	57 (54%)
Sleeve Gastrectomy	N=40		N=32	N=30	N=32	N=33	N=30
0-3	9 (22%)		6 (19%)	6 (20%)	7 (22%)	4 (12%)	4 (13%)
4-9	8 (20%)		7 (22%)	6 (20%)	6 (19%)	7 (21%)	9 (30%)
10+	23 (58%)		19 (59%)	18 (60%)	19 (59%)	22 (67%)	17 (57%)

